Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

editorial

. 2020 Jun 9:10.1097/RLU.0000000000003135. doi: 10.1097/RLU.0000000000003135

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

PET/CT acquisition was performed 1 hour after intravenous infusion of 145 MBq of ¹⁸F-FDG. A, ¹⁸F-FDG PET/CT maximum intensity projection showed an intense uptake (SUVmax 12.8) in anal canal primary neoplasm (black arrow) and increasing uptake in right lung corresponding in axial PET/CT slices to subpleural ground-glass opacity with ¹⁸F-FDG increasing uptake in right upper lobe (SUVmax of 2.4) (B, C), associated with patchy, rounded, diffuse, ground-glass opacity with mild FDG uptake (D, E). This incidental lung lesion finding, even in an asymptomatic patient, was consistent with typical appearance of COVID-19 infection during the March 2020 pandemic.^1–5 There was no evidence of lymph node FDG uptake compared with some prior reported cases.^6,7 The infection was confirmed by reverse transcription–polymerase chain reaction on nasopharyngeal swab collection.